Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has demonstrated operational resilience and is enhancing shareholder returns [1] - In 2025, the company reported a revenue of 28.873 billion yuan, a year-on-year increase of 7.32%, and a net profit attributable to shareholders of 7.038 billion yuan, up 10.95% year-on-year [5] - The company is focusing on internal reforms and product/channel transformation, with a steady growth trend expected to continue [5] - The company has committed to a shareholder return plan, promising that the total cash dividends for 2025-2027 will not be less than 80% of the annual net profit attributable to shareholders [5] Financial Performance - In 2025, the company's revenue growth rate was 7.3%, with projections of 9.2% for 2026, 9.1% for 2027, and 8.9% for 2028 [6] - The net profit attributable to shareholders is expected to grow to 7.778 billion yuan in 2026, 8.480 billion yuan in 2027, and 9.200 billion yuan in 2028, with growth rates of 10.5%, 9.0%, and 8.5% respectively [6] - The company's gross margin for 2025 was 40.22%, an increase of 3.23 percentage points year-on-year, attributed to lower raw material prices and cost control measures [5] Product and Channel Development - The company has established a pyramid-shaped product matrix, with core products like soy sauce, oyster sauce, and seasoning sauce showing steady growth [5] - Online channel revenue grew by 31.87% year-on-year, indicating improved operational capabilities in online sales [5] - The company is actively developing new channels and customized products for online sales, contributing to significant revenue growth [5]

——扬农化工（600486.SH）2025 年报点评 2026 年 3 月 31 日 公司研究 产销量稳步增长业绩修复，持续关注优创项目放量进展 要点 事件：公司发布 2025 年年报。2025 年，公司实现营收 118.70 亿元，同比增长 13.76%；实现归母净利润 12.86 亿元，同比增长 6.98%；实现扣非后归母净利 润 12.72 亿元，同比增长 9.39%。2025Q4，公司单季度实现营收 27.14 亿元， 同比增长 12.20%，环比减少 7.14%；实现归母净利润 2.31 亿元，同比增长 30.81%，环比减少 7.61%。 原药销量稳步释放，驱动公司业绩修复。2025 年，公司原药业务实现营收 73.15 亿元，同比增长 13.97%。在原药价格下跌的背景下，公司原药产销量保持稳健 增长。2025 年公司原药产量为 11.38 万吨，同比增长 17.40%；销量为 11.35 万吨，同比增长 13.62%。公司产销量的提升，主要得益于公司密切产销衔接， 进一步挖掘装置潜能，开展瓶颈工序改造。同时，辽宁优创一期项目多个品种投 产放量亦贡献了增量。2025 年，公司制剂业务实现营收 1 ...

证券研究报告 | [Table_Invest] 公司评级 | 买入-A/买入-H | | --- | --- | | 当前价格 | 90.00 元/75.70 港元 | | 合理价值 | 112.59 元/93.54 港元 | | 前次评级 | 买入/买入 | | 报告日期 | 2026-03-31 | [Table_PicQuote] 相对市场表现 [Table_Summary] 核心观点： 盈利预测： | [Table_ 单位:Finance] 人民币百万元 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 15,127 | 16,193 | 18,282 | 20,317 | 22,382 | | 增长率（ ） % | 7.7% | 7.0% | 12.9% | 11.1% | 10.2% | | EBITDA | 2,358 | 2,554 | 2,904 | 3,306 | 3,683 | | 归母净利润 | 1,485 | 1,359 | 1,706 | 1,971 | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating expected stock price growth exceeding the market benchmark by 5% to 15% over the next six months [4]. Core Insights - The company achieved a record high in revenue for 2025, with total revenue reaching 6.793 billion yuan, a year-on-year increase of 14.63%. The net profit attributable to shareholders was 873 million yuan, reflecting a growth of 6.21% year-on-year [1]. - In Q4 2025, the company reported revenue of 1.722 billion yuan, a significant increase of 33.89% year-on-year, although it saw a slight decline of 1.07% quarter-on-quarter. The net profit for this quarter was 175 million yuan, down 23.19% year-on-year and 12.92% quarter-on-quarter [1]. - The company demonstrated strong operational resilience, with chip sales surpassing 174 million units despite fluctuations in the global semiconductor cycle. The gross margin improved from 36.23% in Q1 to 40.46% in Q4, leading to an annual gross margin of 37.97%, up 1.42 percentage points year-on-year [1]. - The company has made significant advancements in its product offerings, achieving nearly 9 million units in sales of SoC chips based on 6nm technology in 2025, with expectations to reach 30 million units in 2026 [2]. - The company has established a comprehensive platform covering multimedia, connectivity, AIoT, and automotive sectors, enhancing its growth potential through a diversified product lineup [2]. - The company is a leader in edge AI chips, with over 20 self-developed NPU chips already integrated into its products. The shipment of edge AI chips exceeded 20 million units in 2025, marking a year-on-year growth of nearly 160% [3]. - The company has formed deep partnerships with nearly 270 global operators in the B2B sector and collaborated with major companies like Google, Samsung, and Walmart in the B2C sector [3]. - Revenue is projected to grow by 25% to 45% year-on-year, driven by the increasing demand for edge AI computing capabilities [3]. Financial Summary - For 2025, the company reported total revenue of 6,793 million yuan and a net profit of 873 million yuan. The projected revenues for 2026, 2027, and 2028 are 8,916 million yuan, 11,101 million yuan, and 13,626 million yuan, respectively, indicating a compound annual growth rate of 31.25%, 24.50%, and 22.75% [4][10]. - The net profit forecasts for 2026, 2027, and 2028 are 1,461 million yuan, 1,876 million yuan, and 2,310 million yuan, respectively, with corresponding P/E ratios of 23, 18, and 15 [4][10]. - The company’s gross margin is expected to improve, with projections of 38.0% in 2025, 38.9% in 2026, and 39.9% in 2027 and 2028 [10].

非银金融/证券Ⅱ 华泰证券（601688.SH） 扣非净利润同比+80%，财富和海外业务亮点突出 lukun@kysec.cn gaochao1@kysec.cn 证书编号：S0790520050001 证书编号：S0790524040002 扣非净利润同比+80%，自营稳健，财富和海外业务亮点突出 2025 年归母净利润 164 亿，同比+7%，扣非净利润同比+80%，符合我们预期。 2025 年扣非加权 ROE9.13%，同比+3.9pct，期末权益乘数（扣客户保证金）4.04 倍，同比+0.76 倍。我们下调市场交易量、涨跌幅假设，下调 2026、2027 年并新 增 2028 年盈利预测，预计 2026-2028 年归母净利润为 199、218、243 亿（调前 217、251），同比+22%、+9%、+11%，当前股价对应 PE 8.2、7.5、6.8 倍，PB 0.87、 0.80、0.74 倍。公司业务多元，核心子公司利润贡献较高，经纪投行向好，自营 风格稳健，预计 2026 年业绩保持高增，拥抱 AI，引领行业数字金融变革。当前 PB 估值低于 1.0 倍，估值具有安全边际，维持"买入"评级。 ...

Investment Rating - The investment rating for Guobang Pharmaceutical is "Buy" (maintained) [1] Core Views - The company is expected to achieve steady revenue growth in 2025, with projected revenue of 6.011 billion yuan, a year-on-year increase of 2.05%. The net profit attributable to shareholders is forecasted to be 821 million yuan, up 5.02% year-on-year [5] - The animal health segment is anticipated to reach a price turning point, with a significant increase in sales volume for key products such as Florfenicol and Doxycycline [5][6] - The company has adjusted its profit forecasts for 2026-2027, now estimating net profits of 1.060 billion yuan and 1.291 billion yuan respectively, while introducing a new forecast for 2028 with a net profit of 1.467 billion yuan [5] Financial Performance - In 2025, the company achieved a gross margin of 26.03%, an increase of 1.03 percentage points, and a net margin of 13.6%, up 0.35 percentage points [5] - The revenue from the animal health segment was 2.492 billion yuan, reflecting a year-on-year growth of 15.35%, while the pharmaceutical segment saw a decline of 9.08% to 3.475 billion yuan [6] - The company has a high valuation attractiveness with a current price-to-earnings ratio (P/E) of 14.2 for 2026, 11.6 for 2027, and 10.2 for 2028 [5][9] Business Structure and Product Development - The company has optimized its business structure, with over 80 products in production and sales, including 13 products generating over 100 million yuan in revenue [6] - Significant progress in product registration has been made, with several key products receiving international certifications, enhancing the company's competitive position [7] Research and Development - The company maintains a high level of research and development intensity, with a research expense ratio of 3.49% in 2025 [7]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5]. Core Insights - The company achieved a revenue of 4.741 billion yuan in 2025, representing a year-on-year growth of 12.54%, and a net profit attributable to shareholders of 376 million yuan, up 2.74% year-on-year [1]. - In Q4 2025, the company reported a revenue of 1.305 billion yuan, a year-on-year increase of 28.98% and a quarter-on-quarter increase of 9.86%, with a net profit of 120 million yuan, reflecting a significant year-on-year growth of 95.01% and a quarter-on-quarter growth of 128.94% [1]. - The demand in the automotive and industrial sectors is gradually recovering, contributing to the rebound in the company's storage chip business [1]. - The company is actively enhancing its storage business R&D, with several new DRAM chips in mass production, which are expected to significantly improve market competitiveness [2]. - The company has accelerated the launch of new computing chips, including the T33 video processor for security monitoring, which meets the performance and power consumption needs of the market [3]. Summary by Sections Financial Performance - Revenue for 2025 was 4.741 billion yuan, with a growth rate of 12.54% [4]. - The net profit for 2025 was 376 million yuan, with a growth rate of 2.74% [4]. - Forecasted net profits for 2026, 2027, and 2028 are 654 million yuan, 767 million yuan, and 925 million yuan respectively [4]. Product Development - The company has completed testing and mass production of 20nm, 18nm, and 16nm DRAM chips, with ongoing R&D for new process technologies [2]. - New products such as 8Gb DDR4 and LPDDR4 are entering mass production, and LPDDR5 is being developed to meet automotive market demands [2]. Market Position - The company maintains a strong position in the industrial and automotive markets, with expectations for accelerated growth due to new product launches and an upward storage cycle [3].

证券研究报告：食品饮料 | 公司点评报告 发布时间：2026-03-31 股票投资评级 买入 |首次覆盖 个股表现 2025-03 2025-06 2025-08 2025-11 2026-01 2026-03 -14% -11% -8% -5% -2% 1% 4% 7% 10% 海天味业 食品饮料 研究所 分析师:蔡雪昱 SAC 登记编号:S1340522070001 Email:caixueyu@cnpsec.com 分析师:张子健 SAC 登记编号:S1340524050001 Email:zhangzijian@cnpsec.com 海天味业(603288) 深耕内部经营提质，稳健业绩支撑高分红 l 投资要点 公司 2025 年实现营业总收入/营业收入/归母净利润/扣非净利 润 288.73/288.73/70.38/68.45 亿 元 ， 同 比 7.33%/7.33%/10.94%/12.79%。2025 年，公司毛利率/归母净利率为 40.22%/24.38%，分别同比 3.23/0.79pct；销售/管理/研发/财务费用 率 分 别 为 6.7%/2.42%/3.17%/-1.58% ， 分 ...

证 券 研 究 报 告 思特威-W（688213）2025 年报点评 强推（维持） 三大业务协同发力业绩高增，"3+AI"战略构 筑新蓝图 事项： ❖ 思特威发布 2025 年报，公司 25 年实现营收 90.31 亿元（YoY+51.32%），实现 归母净利润 10.01 亿元（YoY+154.94%）。单季度来看，公司 25Q4 实现营收 27.14 亿元（ YoY+54.16%， QoQ+7.24% ）， 实 现 归 母 净 利 润 3.02 亿 元 （YoY+152.54%，QoQ-0.27%）。 评论： [主要财务指标 ReportFinancialIndex] | | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 9,031 | 12,389 | 15,874 | 19,805 | | 同比增速(%) | 51.3% | 37.2% | 28.1% | 24.8% | | 归母净利润(百万) | 1,001 | 1,528 | 2,051 | 2,694 | | 同比增速(%) | 154 ...

证券研究报告 | 2026年03月31日 东方电缆（603606.SH） 优于大市 重大海风项目陆续交付，存货与合同负债高增 全年业绩较快增长，高毛利产品交付提振盈利能力。2025 年公司实现营收 108.43 亿元，同比+19.26%；归母净利润 12.71 亿元，同比+26.11%；扣非净 利润 12.54 亿元，同比+38.01%。2025 年公司毛利率 22.11%，同比+3.28pct.； 净利率 11.73%，同比+0.64pct.。受益于高毛利海缆订单交付，公司盈利能 力明显提升。 下半年业绩表现亮眼，Inch cape、中广核帆石等重点项目实现交付。四季 度公司实现营收 33.45 亿元，同比+39.75%，环比+9.11%；归母净利润 3.57 亿元，同比+370.06%，环比-18.95%；扣非净利润 3.52 亿元，同比+205.38%， 环比-19.92%。四季度毛利率 26.76%，同比+17.23pct.，环比+4.16pct.；净 利率 10.69%，同比+7.51pct.，环比-3.69pct.。 核心观点 公司研究·财报点评 电力设备·电网设备 下半年陆续中标重大海风项目，2 ...